-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS starts Phase 1 trial of SCY-770 AMPK activator in ADPKD program

PUBT·06/30/2026 12:04:40
Listen to the news
SCYNEXIS starts Phase 1 trial of SCY-770 AMPK activator in ADPKD program
  • SCYNEXIS launched a Phase 1 study of SCY-770, an oral AMPK activator being developed for autosomal dominant polycystic kidney disease.
  • Results have not been presented; topline Phase 1 data are expected in Q3 2026.
  • The trial aims to guide dose selection for a Phase 2 proof-of-concept study targeted to start in Q4 2026.
  • SCY-770 has FDA orphan drug designation for ADPKD, supporting a rare-disease development strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754152) on June 30, 2026, and is solely responsible for the information contained therein.